DB04985InvestigationalProtein Based Therapies
Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human...
- Mechanism
- Curator reviewed
The mechanism of action and receptor for PCK3145 suggests PCK3145 to be a signal transduction inhibitor with multiple ways (apoptosis, anti-angiogenesis and anti-metastasis) to restrict disease development.
- Primary indication
- For the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.Curator reviewed
- Code names
- PCK-3145
Resolves to
Compound
Targets
What you can answer from here — as of October 01, 2026
Which drugs share a target with Tigapotide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account